Table 2.
Symptoms in patients on somatostatin analogue treatment for metastatic disease from small-intestinal neuroendocrine tumour EORTC QLQ-C30 values expressed as mean (standard deviation). A higher score (1–100) on functional scales represents a higher level of function, while a higher score (1–100) on symptom scales represents a higher level of symptoms
| Baseline | 1-year follow-up | |
|---|---|---|
| Functional scores | ||
| Global health status | 72.5 (20.4) | 75.5 (18.7) |
| Physical functioning | 80.2 (20.6) | 82.0 (19.1) |
| Role functioning | 77.5 (27.9) | 78.4 (23.7) |
| Emotional functioning | 83.1 (21.9) | 85.4 (17.3) |
| Cognitive functioning | 79.0 (19.0) | 81.4 (17.3) |
| Social functioning | 71.4 (25.5) | 78.8 (24.6) |
| Financial difficulties | 5.3 (15.1) | 5.6 (14.7) |
| Symptom scores | ||
| Fatigue | 35.3 (23.0) | 34.4 (22.1) |
| Nausea and vomiting | 5.5 (10.3) | 4.8 (9.7) |
| Pain | 22.9 (28.2) | 19.3 (25.9) |
| Dyspnoea | 25.2 (28.9) | 22.5 (25.6) |
| Insomnia | 30.7 (36.5) | 25.4 (29.8) |
| Appetite loss | 9.1 (21.9) | 7.0 (20.6) |
| Constipation | 14.0 (21.9) | 10.5 (19.0) |
| Diarrhoea | 51.5 (32.7) | 42.2 (31.7) |